INmune Bio and UK charity Anthony Nolan have expanded their collaboration to enhance the CORDStrom™ MSC platform, using high-quality umbilical cord tissue to develop consistent, scalable cell therapies. This partnership targets treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), oncology, and inflammatory diseases like osteoarthritis and lupus. The agreement ensures regulatory compliance and quality standards, leveraging Anthony Nolan's expertise in stem cell sourcing. This strategic move aims to overcome previous challenges in MSC therapy consistency and advance new treatments toward commercial approval.
Alstom and its consortium partners have reached financial close for the Haifa-Nazareth light rail project in Israel, a major step enabling full-scale execution. The €2 billion project will build a 41-kilometer light rail line connecting Haifa, Nazare...
Alstom and its partners have finalized financing for the Haifa-Nazareth light rail project in Israel, valued at around €2 billion, with Alstom's share at approximately €750 million. The 41-kilometer line will connect Haifa, Nazareth, and nearby commu...
The global strategy consulting market, valued at $81.51 billion in 2025, is projected to grow to $194.56 billion by 2035 with a CAGR of 9.09%. Growth is fueled by increasing demand for digital transformation, AI-powered advisory services, ESG consult...
Broadcom is recommended as a buy due to its consistent earnings per share growth, strong competitive advantages in networking, and robust business fundamentals. Its Ethernet switching and co-packaged optics businesses remain resilient against risks f...
Alibaba's Cloud Intelligence Group has achieved a 46.1% average annual growth rate over the past decade, outpacing the overall company growth. This growth is supported by increased AI adoption and improved profit margins. Despite a decline in global ...
